Search
Barbexaclone
go.drugbank.com/drugs/DB09001ExperimentalBarbexaclone, a salt compound of propylhexedrine and phenobarbital, is a potent antiepileptic. By weight, barbexaclone is 40% propylhexedrine and 60% phenobarbital. … These reports were conducted in a small series of patients in the 1970s and 1980s, and have yet to be confirmed by larger controlled trials.
Categories: Cytochrome P-450 CYP3A Inducers, Cytochrome P-450 CYP3A4 InducersClocapramine
go.drugbank.com/drugs/DB09003ExperimentalClocapramine has been implicated in at least one strange death, including a suicide.
Categories: Heterocyclic Compounds, 3-RingBeclamide
go.drugbank.com/drugs/DB09011ExperimentalBeclamide (N-benzyl-B-chloropropionamide) is a no longer used drug that possesses anticonvulsant and sedative activity.
Brotizolam
go.drugbank.com/drugs/DB09017ApprovedWithdrawnBrotizolam is indicated for 2-4 weeks of treatment for severe or debilitating insomnia. … Brotizolam is a sedative-hypnotic thienodiazepine drug which is a benzodiazepine analog. It demonstrates anxiolytic, anticonvulsant, hypnotic, sedative and skeletal muscle relaxant effects.
International brands: Brotizolam MCategories: Cytochrome P-450 Substrates, Heterocyclic Compounds, 1-RingNivolumab
go.drugbank.com/drugs/DB09035ApprovedInvestigationalNivolumab is a fully human IgG4 antibody targeting the immune checkpoint programmed death receptor-1 (PD-1).
Mixtures: OPDUALAG® SOLUCION INYECTABLECategories: PD-1/PDL-1 (Programmed cell death protein 1/death ligand 1) inhibitors, PD-1/PD-L1 (Programmed cell death protein 1/death ligand 1) inhibitorsDulaglutide
go.drugbank.com/drugs/DB09045ApprovedInvestigationalDulaglutide, marketed by Eli Lilly as Trulicity, is a once-weekly subcutaneous glucagon-like peptide-1 (GLP-1) receptor agonist designed using recombinant DNA technology; it has been approved as an adjunct … therapy to diet and exercise in the management of 2 diabetes (T2DM).
Categories: Glucagon-like peptide-1 (GLP-1) analogues, GLP-1 AgonistsProducts: TRULICITY® 1.5 MG/0.5 ML, TRULICITY® 0.75 MG/0.5 MLNetupitant
go.drugbank.com/drugs/DB09048ApprovedInvestigationalNetupitant is a neurokinin 1 receptor antagonist. The combination drug is marketed by Eisai Inc. and Helsinn Therapeutics (U.S.) Inc. under the brand Akynzeo.
Synonyms: 2-[3,5-Bis(trifluoromethyl)phenyl]-N,2-dimethyl-N-[4-(2-methylphenyl)-6-(4-methyl-1-piperazinyl)-3-pyridinyl]propanamideCategories: Substance P/Neurokinin-1 Receptor Antagonist, Neurokinin 1 AntagonistsElosulfase alfa
go.drugbank.com/drugs/DB09051ApprovedInvestigationalElosulfase alfa is a synthetic version of the enzyme N-acetylgalactosamine-6-sulfatase. It was approved by the FDA in 2014 for the treatment of Morquio syndrome. … The recommended dose is 2 mg per kg given intravenously over a minimum range of 3.5 to 4.5 hours, based on infusion volume, once every week.
Synonyms: Recombinant human N-acetylgalactosamine-6-sulfatase, Recombinant human N-acetylgalactosamine-6-sulfatase (rhGALNS)Products: VIMIZIM® 1MG/ML SOLUCIÓN CONCENTRADA PARA INFUSIÓNTibolone
go.drugbank.com/drugs/DB09070ApprovedInvestigationalTibolone is a synthetic steroid hormone drug, which is mainly non-selective in its binding profile, acting as an agonist primarily at estrogen receptors (ER), with a preference for ER alpha [L1874]. … In June 2006, Organon Pharmaceuticals announced the receipt of a Not Approvable Letter from the U.S.
Synonyms: 17-hydroxy-7alpha-methyl-19-nor-17alpha-pregn-5(10)-en-20-yn-3-oneProducts: HOLIK-B, TINOX®.Pinaverium
go.drugbank.com/drugs/DB09090ApprovedInvestigationalPinaverium is a spasmolytic agent used for functional gastrointestinal disorders. It is a quaternary ammonium compound that acts as an atypical calcium antagonist to restore normal bowel function. … Although it is not a currently approved drug by the FDA, pinaverium is available in over 60 countries including Canada.
Mixtures: BROMUX D® 100/300 MG CÁPSULA., DUOTRYNE®Categories: Cytochrome P-450 Substrates, Heterocyclic Compounds, 1-Ring